Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Shire’s Japanese takeover confirmed, but what does it say about London’s blue-chips?

Deal capital is clearly sloshing around blue-chip boardrooms, but, are we seeing a run of takeovers near the top of the market?
representing takeovers, aquisitions and mergers
Takeda wiill pay the equivalent of £48.17 per share

So, it has been confirmed that Shire Plc’s (LON:SHP) management will back the proposed takeover offer from Japan’s Takeda Pharmaceutical Company at the equivalent of £48.17 per share.

Two weeks ago Shire claimed it would be willing to recommend Takeda’s improved cash plus shares approach, as a fortnight of mutual due-diligence effectively began.

That evidently culminated in today’s recommended deal. It came as the ‘put up or shut up’ offer deadline was due to expire today.

Takeda is to pay US$30.33 per Shire share in cash with the balance paid in equity (either 0.839 Tokyo listed shares or 1.678 American Depository Securities).

READ: Shire succumbs to £46bn Takeda bid

In all the deal values Shire at £46bn, and, according to Takeda, it will create a R&D driven biopharmaceutical leader incorporated and headquartered in Japan.

“We firmly believe that this combination recognizes the strong growth potential of our leading products and innovative pipeline and is in the best interests of our shareholders, our patients and the communities we serve," said Shire chairman Susan Kilsby.

Undoubtedly, it is a big and significant deal and, as is customary for such transactions, there’ll be a certain amount of scrutiny and regulatory obstacles to navigate.

Various international clearances will be needed, and, of course, both company’s shareholders will have to give the go ahead.

 In this regard, it should be noted that analysts saw Takeda’s final offer as being near the maximum of what would be possible so, perhaps, it remains to be seen just how supportive Japanese stakeholders will of the valuation terms. These are questions for other days, however.

Investors and market speculators alike, will now digest the valuation points and there’ll be the usual analysis and arbitrage as the transaction moves forward.

Importantly, there are other questions for investors to ask themselves beyond this deal.

From a sector perspective, it’s fair to say we’ve become accustomed to consolidation as a masquerade of growth - Valeant is probably the most well-known example, though, there are plenty others.

Corporate bartering and consolidatory axe-welding can, generally, be more predictably modelled than any clinical trial result can be forecasted.

And so it is that pharmaceutical portfolios seem to be perennially combined through ever larger mergers and takeovers.Dublin headquartered, London listed Shire has been in the M&A crosshairs for quite some time, with prior potential transactions mooted.

Abbvie’s aborted US$54bn deal was the most notable, and in the meantime the company itself acquired rare disease specialist Baxalta for US$32bn.

Deal capital is evidently sloshing around

As one of several big money deals presently on the table, the Shire-Takeda tie-up has some broader significance.

Valued at a proposed £46bn, the pharma-deal is in rich company.

Sainsbury is to merge with Walmart’s ASDA in a £10bn deal, Tesco is absorbing Booker, meanwhile, Melrose has taken out GKN for £8bn.

SSE’s proposed £7bn merger with Npower has been lined up for an in-depth investigation amid competition concerns.

First Group Plc (LON:FGP) was targeted (but then dropped) by private equity group, meanwhile, Virgin Money has been the subject of a £1.6bn approach by Clydesdale and Yorkshire Banking Group.

Comcast and Fox (and Disney) are tussling over a possible takeover of Sky.

Meanwhile, Amazon is being linked to any and every brick and mortar retail group with a decent property portfolio.

There’s an abundance of deal capital sloshing around the world’s blue-chip boardrooms and markets have been decidedly bullish for some time.

But, at the same time, only a casual glance across the political and economic headlines suggests macro-risks aplenty.

Some may likely question whether we’re seeing a run of deals near the top of the market, and, whether such a corporate flurry of activity may be a harbinger of a market that’s running out of new ideas.

Political and economic volatility

Brexit is still a screaming uncertainty, with tetchy negotiations and now with less than a year left on the countdown.

American politics seemingly resembles a polarising soap-opera, with President Trump seemingly bouncing from one potential flashpoint or scandal to another.

Meanwhile, the West’s relationship with China and Russia (with now fourth-time elected President Vladimir Putin) has appeared somewhat more confrontational – evidenced by diplomatic spats and trade standoffs. And, all that is before one begins to look to the minefield of issues in the Middle East.

Economically, much of the recent attention has been on interest rates and currency values - frankly, there are few other stock market catalysts about at present.

It has been about ten years since the global financial crisis led to unprecedented low interest rates, and, whilst the Federal Reserve has been creeping the US rate higher one quarter point at a time, the Bank of England and the ECB are having a tougher balancing act.

Price inflation is evident, living costs remain high and while austerity may be less of a political buzzword its effects haven’t gone anywhere.

The most recent economic statistics showed the UK has just muddled through one its slowest quarters for growth since the Brexit vote - experts forecast Q1 GDP at a measly 0.2% following the April PMI data - and patchy retail results suggest consumer spending was also weak.

In London, the FTSE 100 has held close to its all-time highs through recent weeks despite all the risks and apparent weaknesses. At around 7,567 on Tuesday, thanks partly to the increased interest in Shire, the London index is in relative striking distance from the recent ‘top’ at around 7,778.

So, whilst the London-listed multi-nationals and their worldwide counterparts look to big money consolidation, it is hard to not hesitate and wonder just how much real world growth remains right now.

View full SHP profile View Profile

Shire Plc Timeline

Related Articles

test tubes
September 11 2018
Sierra Oncology is about to start the third trial of Sareum’s SRA737 Chk1 inhibitor, while internally, Sareum is making “good progress” with its TYK2 inhibitor programme
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use